Vir Biotechnology Inc V.VIR

Primary Symbol: VIR

Healthcare Biotechnology

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

NDAQ:VIR - Post by User

Vir Biotechnology Inc > the biggest fear I have ….

<< Previous

Bullboard Posts

Next >>

Comment by WeedStudyon Apr 26, 2019 6:50pm

87 Views

Post# 29677473

RE:RE:the biggest fear I have ….

Buylowerthanmos is wrong. There was a private placement a year and half ago done at 60cents. When the stock came off halt it jumped up to about $2.00, but that had nothing to do with the private placement. The private placement does not control where the stock opens or trades

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading